OBJECTIVES: Although in younger patients indications for biological prosthesis implantation in mitral valve replacement remain controversial, recently bioprostheses use increased considerably. We present late results obtained with the Medtronic Mosaic bioprosthesis in patients aged 65 years or younger. METHODS: Between 2007 and 2017, 67 mitral Mosaic bioprostheses were implanted in patients aged 65 years or younger (58.5 ± 6.4 years). Follow-up extended up to 13 years. Survival, freedom from structural valve degeneration, endocarditis, thromboembolic events and reoperation were considered as main clinical end points evaluated at 1, 5 and 10 years. RESULTS: The mean follow-up was 4.7 ± 2.8 years. Overall mortality rate was 12%. At 1, 5 and 10 years, survival was 94 ± 3%, 89 ± 4% and 77 ± 9%, respectively. Freedom from structural valve degeneration was 100%, 94 ± 4% and 71 ± 21%. Freedom from endocarditis was 95 ± 3%, 90 ± 6% and 84 ± 8%. Freedom from thromboembolic events was 94 ± 3%, 90 ± 5% and 90 ± 5%. Freedom from reoperation was 94 ± 3%, 87 ± 5% and 65 ± 19%. CONCLUSIONS: Mosaic bioprosthesis appears a valid mitral valve substitute even when employed in ≤65-year-old patients.
OBJECTIVES: Although in younger patients indications for biological prosthesis implantation in mitral valve replacement remain controversial, recently bioprostheses use increased considerably. We present late results obtained with the Medtronic Mosaic bioprosthesis in patients aged 65 years or younger. METHODS: Between 2007 and 2017, 67 mitral Mosaic bioprostheses were implanted in patients aged 65 years or younger (58.5 ± 6.4 years). Follow-up extended up to 13 years. Survival, freedom from structural valve degeneration, endocarditis, thromboembolic events and reoperation were considered as main clinical end points evaluated at 1, 5 and 10 years. RESULTS: The mean follow-up was 4.7 ± 2.8 years. Overall mortality rate was 12%. At 1, 5 and 10 years, survival was 94 ± 3%, 89 ± 4% and 77 ± 9%, respectively. Freedom from structural valve degeneration was 100%, 94 ± 4% and 71 ± 21%. Freedom from endocarditis was 95 ± 3%, 90 ± 6% and 84 ± 8%. Freedom from thromboembolic events was 94 ± 3%, 90 ± 5% and 90 ± 5%. Freedom from reoperation was 94 ± 3%, 87 ± 5% and 65 ± 19%. CONCLUSIONS: Mosaic bioprosthesis appears a valid mitral valve substitute even when employed in ≤65-year-old patients.
Authors: D J Thomson; W R Jamieson; J G Dumesnil; J J Burgess; C M Peniston; J Métras; J A Sullivan; J C Parrott; A Maitland; I J Cybulsky Journal: Ann Thorac Surg Date: 2001-05 Impact factor: 4.330
Authors: Yuting P Chiang; Joanna Chikwe; Alan J Moskowitz; Shinobu Itagaki; David H Adams; Natalia N Egorova Journal: JAMA Date: 2014-10-01 Impact factor: 56.272
Authors: Nicola Luciani; Eugenio Mossuto; Davide Ricci; Marco Luciani; Marco Russo; Antonio Salsano; Alberto Pozzoli; Michele D Pierri; Augusto D'Onofrio; Giovanni A Chiariello; Franco Glieca; Alberto Canziani; Mauro Rinaldi; Paolo Nardi; Valentina Milazzo; Enrico M Trecarichi; Francesco Santini; Michele De Bonis; Lucia Torracca; Eleonora Bizzotto; Mario Tumbarello Journal: Eur J Cardiothorac Surg Date: 2017-10-01 Impact factor: 4.191
Authors: Sung-Han Yoon; Brian K Whisenant; Sabine Bleiziffer; Victoria Delgado; Niklas Schofer; Lena Eschenbach; Buntaro Fujita; Rahul Sharma; Marco Ancona; Ermela Yzeiraj; Stefano Cannata; Colin Barker; James E Davies; Antonio H Frangieh; Florian Deuschl; Tomaz Podlesnikar; Masahiko Asami; Abhijeet Dhoble; Anthony Chyou; Jean-Bernard Masson; Harindra C Wijeysundera; Daniel J Blackman; Rajiv Rampat; Maurizio Taramasso; Enrique Gutierrez-Ibanes; Tarun Chakravarty; Guiherme F Attizzani; Tsuyoshi Kaneko; S Chiu Wong; Horst Sievert; Fabian Nietlispach; David Hildick-Smith; Luis Nombela-Franco; Lenard Conradi; Christian Hengstenberg; Michael J Reardon; Albert Markus Kasel; Simon Redwood; Antonio Colombo; Saibal Kar; Francesco Maisano; Stephan Windecker; Thomas Pilgrim; Stephan M Ensminger; Bernard D Prendergast; Joachim Schofer; Ulrich Schaefer; Jeroen J Bax; Azeem Latib; Raj R Makkar Journal: J Am Coll Cardiol Date: 2017-08-29 Impact factor: 24.094
Authors: James S Gammie; Shubin Sheng; Bartley P Griffith; Eric D Peterson; J Scott Rankin; Sean M O'Brien; James M Brown Journal: Ann Thorac Surg Date: 2009-05 Impact factor: 4.330